Health Care Access and Use Among Adults with Diabetes During the COVID-19 Pandemic — United States, February–March 2021

Diabetes affects approximately one in 10 persons in the United States† and is a risk factor for severe COVID-19 (1), especially when a patient's diabetes is not well managed (2). The extent to which the COVID-19 pandemic has affected diabetes care and management, and whether this varies across age groups, is currently unknown. To evaluate access to and use of health care, as well as experiences, attitudes, and behaviors about COVID-19 prevention and vaccination, a nonprobability, Internet-based survey was administered to 5,261 U.S. adults aged ≥18 years during February-March 2021. Among respondents, 760 (14%) adults who reported having diabetes currently managed with medication were included in the analysis. Younger adults (aged 18-29 years) with diabetes were more likely to report having missed medical care during the past 3 months (87%; 79) than were those aged 30-59 years (63%; 372) or ≥60 years (26%; 309) (p<0.001). Overall, 44% of younger adults reported difficulty accessing diabetes medications. Younger adults with diabetes also reported lower intention to receive COVID-19 vaccination (66%) compared with adults aged ≥60 years§ (85%; p = 0.001). During the COVID-19 pandemic, efforts to enhance access to diabetes care for adults with diabetes and deliver public health messages emphasizing the importance of diabetes management and COVID-19 prevention, including vaccination, are warranted, especially in younger adults.

[1]  D. Hessler,et al.  Cross-national comparison of psychosocial well-being and diabetes outcomes in adults with type 1 diabetes during the COVID-19 pandemic in US, Brazil, and Iran , 2021, Diabetology & Metabolic Syndrome.

[2]  In-kyu Lee,et al.  Impact of urgently initiated tele-prescription due to COVID-19 on glycemic control in patients with type 2 diabetes , 2021, The Korean journal of internal medicine.

[3]  S. Gitelman,et al.  Youth with Type 1 Diabetes had Improvement in Continuous Glucose Monitoring Metrics During the COVID-19 Pandemic. , 2021, Diabetes technology & therapeutics.

[4]  A. Salonia,et al.  Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis , 2021, Reviews in Endocrine and Metabolic Disorders.

[5]  A. Alfadda,et al.  The impact of a prolonged lockdown and use of telemedicine on glycemic control in people with type 1 diabetes during the COVID-19 outbreak in Saudi Arabia , 2021, Diabetes Research and Clinical Practice.

[6]  A. Fryer,et al.  Impact of the UK COVID‐19 pandemic on HbA1c testing and its implications for diabetes diagnosis and management , 2020, International journal of clinical practice.

[7]  D. Klonoff,et al.  Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis , 2020, Diabetes Care.

[8]  G. Alonso,et al.  Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID‐19: Data from a multi‐site surveillance registry , 2020, Journal of diabetes.

[9]  W. Polonsky,et al.  The early impact of the COVID-19 pandemic on adults with type 1 or type 2 diabetes: A national cohort study , 2020, Journal of Diabetes and its Complications.

[10]  K. Khunti,et al.  Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study , 2020, The Lancet Diabetes & Endocrinology.